Immunocore (NASDAQ:IMCR) Posts Quarterly Earnings Results, Beats Estimates By $0.50 EPS

Immunocore (NASDAQ:IMCR) posted its earnings results on Wednesday. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.50, Briefing.com reports. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The firm had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. During the same period in the previous year, the business posted ($0.59) EPS. The business’s revenue was up 23.7% compared to the same quarter last year.

Immunocore Trading Up 2.5 %

Shares of NASDAQ IMCR traded up $0.83 during trading on Thursday, reaching $34.34. The company had a trading volume of 189,433 shares, compared to its average volume of 527,179. The company’s fifty day moving average price is $32.67 and its 200-day moving average price is $39.70. Immunocore has a 12 month low of $29.72 and a 12 month high of $76.98. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. The stock has a market cap of $1.72 billion, a P/E ratio of -32.14 and a beta of 0.72.

Wall Street Analyst Weigh In

IMCR has been the subject of several recent analyst reports. Needham & Company LLC reduced their price objective on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday. JPMorgan Chase & Co. lowered their price objective on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 10th. Morgan Stanley reduced their target price on shares of Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Oppenheimer reiterated an “outperform” rating and set a $89.00 price objective (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Finally, Barclays dropped their target price on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $73.73.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.